TY  - CHAP
M1  - Book, Section
TI  - Alternative Donor Transplants: Haploidentical Hematopoietic Stem Cell Transplantation
A1  - Gaballa, Sameh
A1  - Champlin, Richard E.
A1  - Ciurea, Stefan O.
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
PY  - 2016
T2  - The MD Anderson Manual of Medical Oncology, 3e
AB  - Haploidentical  stem  cell  transplantation  (haploSCT)  from  a  first-degree-related  haplotype-mismatched  donor  (siblings,  children,  parents)  could  expand  allogeneic  stem  cell  transplantation  (SCT)  to  a  large  proportion  of  patients  with  hematologic  malignancies  without  an  HLA-matched  donor  (1).  As  the  average  family  size  continues  to  shrink,  the  likelihood  of  finding  an  HLA-matched  related  sibling  donor  continues  to  decrease  (2).  Moreover,  as  the  population  continues  to  age,  finding  a  young,  healthy  sibling  donor  becomes  increasingly  less  likely.  The  use  of  matched  unrelated  donors  (MUDs)  is  limited  by  the  long  time  to  SCT  (median  3-4  months),  which  makes  it  difficult  to  treat  patients  with  more  advanced  disease  in  rapid  need  of  SCT.  The  ethnicity/race  of  the  recipient  can  also  limit  MUD  transplantation  as  approximately  30%  of  Caucasians,  70%  of  Hispanics,  and  90%  of  African  Americans  do  not  have  a  MUD  in  the  worldwide  registries  (3).  
SN  - 
PB  - McGraw-Hill Medical
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1126741316
ER  -